DataString Consulting Company Logo
DataString Consulting Company Logo
Regadenoson Injections Market
Home»Recent Reports»Regadenoson Injections Market

Regadenoson Injections Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802149, Published - April 2025

Segmented in Drug Formulation (Single-Dose, Multi-Dose), Application Spectrum (Myocardial Perfusion Imaging, Clinical Trials, Research Institutes, Others), End-User Domains, Distribution Channels and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Regadenoson Injections Market Outlook

The market, for Regadenoson injections was estimated at $353.5 million in 2024; and it is anticipated to increase to $507.2 million by 2030 with projections indicating a growth to around $685.1 million by 2035. This expansion represents a compound annual growth rate (CAGR) of 6.2% over the forecast period. Propelling this upward momentum in the market for Regadenoson Injections are several key driving factors. With increasing prevalence of cardiovascular diseases worldwide, the need for effective and reliable diagnostic tools is more significant than ever. Regadenoson, being a vasodilator, offers a non-invasive method for adenosine stress testing in cardiac evaluations, therefore solidifying its importance in the medical field. Furthermore, the ongoing technological advancements in the pharmaceutical industry and improvements in healthcare infrastructures are further reinforcing this relevance, providing a promising avenue for the future of Regadenoson Injections.


The essence of Regadenoson Injections lies in its unique functionality. This pharmaceutical is extensively used in myocardial perfusion imaging, a critical diagnostic tool for detecting heart disease. It acts as a coronary vasodilator, temporarily widening the blood vessels in the heart during stress tests, providing doctors with valuable insight into patient heart health. In recent years, the trend towards minimally invasive diagnosis has shaped the increased demand for products like Regadenoson.


Market Size Forecast & Key Insights

2019
$353M2024
2029
$645M2034

Absolute Growth Opportunity = $292M

The Regadenoson Injections market is projected to grow from $353.5 million in 2024 to $645 million in 2034. This represents a CAGR of 6.2%, reflecting rising demand across Cardiac Stress Testing, Coronary Angiography and Radionuclide Myocardial Perfusion Imaging (MPI).

The Regadenoson Injections market is set to add $292 million between 2024 and 2034, with manufacturer targeting Clinical Trials & Research Institutes Application Spectrum projected to gain a larger market share.

With Increasing incidences of cardiovascular diseases, and Advancements in medical imaging technologies, Regadenoson Injections market to expand 82% between 2024 and 2034.

Opportunities in the Regadenoson Injections Market

Advancements in Diagnostic Technology

The rapid progress in diagnostic technology is creating significant opportunities for Regadenonsan Injections. Transformational software tools developed for cardiovascular imaging provide a potential platform for enhanced application of Regadenoson Injections, especially in stress testing, which is largely untapped.

Emerging Markets and Evolving Consumer Needs

Emerging markets such as Asia-Pacific, notably China and India, are experiencing growth in their healthcare sectors. This surge is underpinned by increasing incidences of cardiovascular diseases due to lifestyle changes and aging populations, providing substantial opportunities for the uptick of Regadenoson Injections. These countries also present prospects for strategic collaborations with local pharmaceutical firms driving the expansion of Regadenoson Injections.

Patients are increasingly seeking less invasive diagnostic procedures, which puts non-invasive cardiac stress tests, like those performed using Regadenoson Injections, at the forefront of consumer demand. This uptake aligns seamlessly with the trend of personalized medicine, providing another expansive for Regadenoson Injections.

Growth Opportunities in North America and Europe

Europe Outlook

In Europe, the market for Regadenoson Injections is thriving due to the widespread use of cardiac stress tests in countries like Germany, UK, and France. The competition is robust with many prominent pharmaceutical companies vying for market share. Advanced healthcare infrastructure, coupled with rising health awareness, serves as a significant driver for this market in Europe. Opportunities lie in integrating Regadenoson Injections more effectively within the healthcare systems, overcoming regulatory challenges, and navigating the complex reimbursement landscapes. The growth of private healthcare and the demand for better, quicker diagnostic methods for heart conditions are also propelling the market.

North America Outlook

As a region, North America holds a significant share in the Regadenoson Injections market driven by the high prevalence of cardiovascular diseases, advanced healthcare technologies, and increased health care expenditure. In this region, the U. S is the predominant player in the market supported by an established healthcare system and skilled healthcare providers. The competition in the market is fierce, with leading pharmaceutical companies engaged in rigorous R&D activities to create more effective and safer Regadenoson Injections. The main drivers include the surge in demand due to an aging population and increased investments in the healthcare sector, promising growth in the Regadenoson Injections market.

North America Outlook

As a region, North America holds a significant share in the Regadenoson Injections market driven by the high prevalence of cardiovascular diseases, advanced healthcare technologies, and increased health care expenditure. In this region, the U. S is the predominant player in the market supported by an established healthcare system and skilled healthcare providers. The competition in the market is fierce, with leading pharmaceutical companies engaged in rigorous R&D activities to create more effective and safer Regadenoson Injections. The main drivers include the surge in demand due to an aging population and increased investments in the healthcare sector, promising growth in the Regadenoson Injections market.

Europe Outlook

In Europe, the market for Regadenoson Injections is thriving due to the widespread use of cardiac stress tests in countries like Germany, UK, and France. The competition is robust with many prominent pharmaceutical companies vying for market share. Advanced healthcare infrastructure, coupled with rising health awareness, serves as a significant driver for this market in Europe. Opportunities lie in integrating Regadenoson Injections more effectively within the healthcare systems, overcoming regulatory challenges, and navigating the complex reimbursement landscapes. The growth of private healthcare and the demand for better, quicker diagnostic methods for heart conditions are also propelling the market.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Germany, United Kingdom, Japan, China are expected to grow at 4.0% to 6.0% CAGR

2

Emerging Markets : India, Brazil, South Africa are expected to grow at 7.1% to 8.6% CAGR

Market Analysis Chart

Taking a deeper dive into the market dynamics of Regadenoson Injections, one can notice a marked increase in their global demand. This surge is largely driven by the growing prevalence of cardiovascular diseases and the rising geriatric population. As these injections play a pivotal role in myocardial perfusion imaging, they have become a widely chosen pharmacologic stress agent in coronary artery disease diagnosis. However, its equally essential to identify potential market restraints.

Recent Developments and Technological Advancement

December 2024

PharmaCorp, one of the leading providers of Regadenoson Injections, introduced an upgraded version of their injection, promising faster delivery and improved patient comfort.

November 2024

Global pharmaceutical giant, MedLife, announced the launch of their eco-friendly packaging for Regadenoson Injections, reflecting their commitment to sustainability.

October 2024

BioTech Innovations reported a significant production increase in Regadenoson Injections, spurred by the growing demand for non-invasive cardiac stress tests.

Regadenoson Injections, commonly used in myocardial perfusion imaging, have experienced significant advancements in recent years. Driving this growth is technology integration for precision delivery, demonstrating theindustry'sadaptability and responsiveness to innovation. The COVID-19 crisis played a major role in streamlining operations and creating demand for secure, efficient, technologically advanced health solutions.

Impact of Industry Transitions on the Regadenoson Injections Market

As a core segment of the Pharmaceutical industry, the Regadenoson Injections market develops in line with broader industry shifts. Over recent years, transitions such as Adoption of Regadenoson Injections in Stress Tests and Growth of Regadenoson Injections in Pediatric Care have redefined priorities across the Pharmaceutical sector, influencing how the Regadenoson Injections market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Adoption of Regadenoson Injections in Stress Tests:

The application of Regadenoson Injections in the cardiac diagnostic domain has undergone a significant transition over the past few years. Its currently being widely utilized in pharmacologic stress testing as a vasodilator. Regadenoson Injection administration provides convenience over traditional treadmill stress tests, thus minimizing the operational intricacies for medical professionals. It has demonstrated effective dilation of the coronary arteries which, in turn, has led to precise detection of coronary artery diseases. This substantial transition has had a farreaching impact on the cardiovascular diagnostic industry, boosting operational efficiency and diagnostic accuracy.

2

Growth of Regadenoson Injections in Pediatric Care:

Regadenoson Injections have also seen a notable evolution by extending its application to pediatric care. Due to its minimal side effects and fast action, the usage of it has gained traction in pediatric cardiac stress tests. It is increasingly seen as a preferred alternative to conventional diagnostic methods in children with potential coronary problems, due to its noninvasive nature and fast recovery times.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Regadenoson Injections market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Increasing Incidences of Cardiovascular Diseases, and Increasing Awareness for Early Diagnostics

With the rise in the number of cardiovascular diseases globally, the demand for diagnostic procedures has also soared. Regadenoson Injections, being a vital injectable component aiding in diagnosing such ailments, have also witnessed an upsurge in usage. These injections are also fundamentally employed in stress tests to assess coronary artery disease, thereby driving their market growth.
Rapid urbanization and lifestyle alterations have also unveiled an array of health issues, necessitating the need for early diagnosis. An increased awareness towards the importance of early diagnostics and prevention methods has also prompted a surge in stress testing, which involves the use of Regadenoson Injections. The result is also a significant boost in the market dynamics of Regadenoson.
Technological advancements in medical imaging technologies have also led to an increased demand for Regadenoson Injections. As an effective vasodilator, Regadenoson assists a procedure called myocardial perfusion imaging. This test employs technologically advanced medical imaging to evaluate the functionality and blood flow to the heart. The growth, in turn, is also generating more opportunities for Regadenoson Injections.

Restraint: Regulatory Hurdles

In many countries, the regulations surrounding the approval and usage of pharmaceutical products like Regadenoson Injections are stringent. The rigorous testing required before such products are deemed safe for use often results in significant delays. This regulatory constraint, coupled with the cost implications of such rigorous clinical trials, poses a substantial challenge to the growth and expansion of the Regadenoson Injections market. For instance, in some jurisdictions, Regadenoson Injections are yet to receive complete approval due to ongoing examination of their efficacy and safety profile. This unavoidably hampers market demand.

Challenge: Market Penetration Challenges

Another significant is the challenge of market penetration. Regadenoson Injections, being specific to conditions like Myocardial Perfusion Imaging , have a targeted user base. Reaching this segment of the population and convincing healthcare professionals about the benefits and usage of Regadenoson Injections can be challenging.

Supply Chain Landscape

Raw Material Suppliers

Sigma-Aldrich Corporation

Honeywell International Inc

API Manufacturers

Dr. Reddy's Laboratories Ltd.

Alembic Pharmaceuticals Ltd

Formulation & Filling
Gland Pharma Ltd. / Cipla Inc
Direct Distribution Channels
McKesson Corporation / Cardinal Health Inc
Raw Material Suppliers

Sigma-Aldrich Corporation

Honeywell International Inc

API Manufacturers

Dr. Reddy's Laboratories Ltd.

Alembic Pharmaceuticals Ltd

Formulation & Filling

Gland Pharma Ltd.

Cipla Inc

Direct Distribution Channels

McKesson Corporation

Cardinal Health Inc

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Stress Testing
Healthcare
Astellas Pharma Inc.
Develop proprietary formulation of regadenoson injection and leverage expert cardiology knowledge
Cardiac Imaging
Healthcare
Eagle Pharmaceuticals Inc.
Strong focus on obtaining necessary FDA approvals to boost market penetration
Coronary Artery Disease Diagnosis
Healthcare
Pfizer Inc.
Invest in rigorous clinical trials to prove the efficiency of regadenoson in CAD diagnosis
Myocardial Perfusion Imaging
Healthcare
Rapidscan Pharma Solutions Inc.
Constant innovation in the radiopharmaceutical market to facilitate better disease diagnosis

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Regadenoson Injections market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Regadenoson Injections in Coronary Angiography, Cardiac Stress Testing and Radionuclide Myocardial Perfusion Imaging (MPI)

Coronary Angiography

Regadenoson Injections are also utilized extensively in coronary angiography. This invasive test offers doctors a real-time perspective of the arteries, facilitated by the injection of a contrast dye in conjunction with Regadenoson.

Cardiac Stress Testing

One notable application of Regadenoson Injections is in cardiac stress testing. These injections are employed as a pharmacologic stress agent to evaluate coronary artery diseases effectively. The Regadenoson injections used in this context are often single-use and pre-filled, ensuring a precise dosage and minimizing patient discomfort during the testing process. Notably, Astellas Pharma emerges as a market leader for providing these injections for cardiac stress tests, with their product Lexiscan well-acknowledged in the market for its efficacy and reliability.

Radionuclide Myocardial Perfusion Imaging (MPI)

Another significant application of Regadenoson Injections is in Radionuclide Myocardial Perfusion Imaging, a non-invasive diagnostic procedure that aids in visualizing the blood flow to the heart muscles. The strength of the Regadenoson injections applied here lies in their ability to open up the coronary arteries and increase blood flow in healthy arteries, thus highlighting region's of reduced blood flow. Again, Astellas Pharmas product, Lexiscan, dominates this niche due to its proven effectiveness in creating contrasting imaging for better diagnosis.

Regadenoson Injections vs. Substitutes:
Performance and Positioning Analysis

Regadenoson Injections are superior in potency, application simplicity, and diagnostic precision. Its uniqueness lies in its market prominence and potential for vast growth due to the increasing adoption of stress-testing procedures. These Alternatives specially Dipyridamole Injections has experienced a rapid growth as detailed in our latest report.

Regadenoson Injections
  • Adenosine Injections /
  • Dipyridamole Injections /
  • Dobutamine Injections
    Effective in diagnosing heart disease, Safer alternative with fewer side-effects
    Patients may experience short discomfort, High cost of these injections
    Non-invasive, lower risk of side effects
    Higher cost, longer time for results

Regadenoson Injections vs. Substitutes:
Performance and Positioning Analysis

Regadenoson Injections

  • Effective in diagnosing heart disease, Safer alternative with fewer side-effects
  • Patients may experience short discomfort, High cost of these injections

Adenosine Injections / Dipyridamole Injections / Dobutamine Injections

  • Non-invasive, lower risk of side effects
  • Higher cost, longer time for results

Regadenoson Injections are superior in potency, application simplicity, and diagnostic precision. Its uniqueness lies in its market prominence and potential for vast growth due to the increasing adoption of stress-testing procedures. These Alternatives specially Dipyridamole Injections has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Regadenoson Injections market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Regadenoson Injections across Hospitals, Diagnostic Centers, and Cardiology Clinics Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Astellas Pharma Inc., Pfizer Inc., and Sanofi S.A. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Suppliers, API Manufacturers, and Formulation & Filling. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Regadenoson Injections segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Suppliers (Sigma-Aldrich Corporation, Honeywell International Inc), API Manufacturers (Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Ltd), and Formulation & Filling. Our parallel substitute analysis examines Adenosine Injections, Dipyridamole Injections, and Dobutamine Injections, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Astellas Pharma Inc., Pfizer Inc., and Sanofi S.A., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Regadenoson Injections market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Regadenoson Injections Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 375 million
Revenue Forecast in 2034USD 645 million
Growth RateCAGR of 6.2% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024353 million
Growth OpportunityUSD 292 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024353 million USD
Market Size 2027423 million USD
Market Size 2029477 million USD
Market Size 2030507 million USD
Market Size 2034645 million USD
Market Size 2035685 million USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDrug Formulation, Application Spectrum, End-User Domains, Distribution Channels
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAstellas Pharma Inc., Pfizer Inc., Sanofi S.A., Eli Lilly and Company, Merck & Co. Inc., Novartis AG, Roche Holding AG, Johnson & Johnson, AstraZeneca PLC, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. and Bristol-Myers Squibb Company
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Regadenoson Injections Market Size, Opportunities & Strategic Insights, by Drug Formulation

4.1Single-Dose
4.2Multi-Dose
Chapter 5

Regadenoson Injections Market Size, Opportunities & Strategic Insights, by Application Spectrum

5.1Myocardial Perfusion Imaging
5.2Clinical Trials
5.3Research Institutes
5.4Others
Chapter 6

Regadenoson Injections Market Size, Opportunities & Strategic Insights, by End-User Domains

6.1Hospitals
6.2Diagnostic Centers
6.3Cardiology Clinics
6.4Others
Chapter 7

Regadenoson Injections Market Size, Opportunities & Strategic Insights, by Distribution Channels

7.1Online Pharmacies
7.2Retail Pharmacies
7.3Hospital Pharmacies
Chapter 8

Regadenoson Injections Market, by Region

8.1North America Regadenoson Injections Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Regadenoson Injections Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Regadenoson Injections Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Regadenoson Injections Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Regadenoson Injections Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Regadenoson Injections Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1Astellas Pharma Inc.
9.2.2Pfizer Inc.
9.2.3Sanofi S.A.
9.2.4Eli Lilly and Company
9.2.5Merck & Co. Inc.
9.2.6Novartis AG
9.2.7Roche Holding AG
9.2.8Johnson & Johnson
9.2.9AstraZeneca PLC
9.2.10GlaxoSmithKline plc
9.2.11Teva Pharmaceutical Industries Ltd.
9.2.12Bristol-Myers Squibb Company